touchOPHTHALMOLOGY posts neuroprotection video

Glaucoma treatment still revolves around one number — intraocular pressure, or IOP. Lowering that pressure helps, often a lot. But vision can keep slipping even when pressure looks controlled, and that is the gap touchOPHTHALMOLOGY is trying to spotlight with a new educational video built around neuroprotection in open-angle glaucoma. The segment, published April 15, 2026, features glaucoma specialist Dr Maria João Menéres and focuses on both primary open-angle glaucoma and steroid-induced open-angle glaucoma, with the pitch that saving retinal ganglion cells may matter alongside pressure control. (youtube.com) ### What did touchOPHTHALMOLOGY actually post? It posted a CME-style educational activity and a shorter YouTube video under the banner “Exploring all angles: Neuroprotective strategies beyond IOP in primary and steroid-induced open-angle glaucoma.” The IME site lists Dr Menéres as faculty, describes the program as CE/CME accredited, and frames it around mechanisms of retinal ganglion cell damage, risk of prog(youtube.com)version says the same thing in shorter form and was posted on April 15. (youtube.com) ### What is neuroprotection here? Basically, it means trying to keep retinal ganglion cells and the optic nerve alive and functioning even after the disease process has started. Pressure lowering targets the plumbing of the eye — less pressure, less mechanical and metabolic stress. Neuroprotection targets the tissue that actually dies and causes permanent vision loss. That is why the video keeps pushing “beyond IOP” rather than “instead of IOP.” (youtube.com) ### Why bring up steroid-induced glaucoma too? Because steroid-induced glaucoma is not some separate curiosity — it is a real secondary open-angle glaucoma where steroids raise outflow resistance and push IOP up, often through changes in the trabecular meshwork. That makes it a useful stress test for the bigger idea. If damage to ganglion cells is the final common pathway in both ordinary and steroid-triggere(youtube.com) in theory, help across both settings while doctors still deal with the pressure problem itself. (touchophthalmologyime.org) ### Why isn’t pressure lowering enough? Because glaucoma is an optic neuropathy, not just a pressure disorder. IOP is the main modifiable risk factor in routine care, but it is not a perfect proxy for whether neurons are safe. Some patients worsen at “normal” pressures, and some steroid-exposed patients can sustain damage quickly if the rise is missed. The whole neuroprotection argument starts there — pressure matters, but pressure is not the whole disease. (touchophthalmologyime.org) ### So is there a proven neuroprotective drug now? That is the catch — not as a standard, approved cornerstone of glaucoma care. The field has talked about neuroprotection for years, and clinicians clearly care about it, but routine management still centers on drops, lasers, and surgery that lower IOP. What touchOPHTHALMOLOGY is reflecting is less a break(touchophthalmologyime.org)se risk does not feel fully captured by tonometry alone. (youtube.com) ### Why does this kind of video matter? Because educational platforms help normalize what counts as “complete” glaucoma care. Once a topic moves from conference chatter into accredited teaching, it usually means clinicians are being nudged to think more broadly in clinic — who is at risk, who needs closer monitoring, and where adjunct strategies might fit. That does not create a new standard overnight. But it(youtube.com)ssure and stop there” toward “lower the pressure and ask what else is damaging the nerve.” (touchophthalmology.com) ### Bottom line? This is an education story, not a drug-approval story. But it is still a meaningful signal: glaucoma specialists are spending more time on the idea that preserving vision may require protecting neurons as well as lowering pressure — especially in steroid-related disease, where damage can accelerate if everyone focuses on the wrong metric. (youtube.com)